Semaglutide vs Tirzepatide: Which GLP-1 Is Right for You?

Two medications. Both GLP-1 receptor agonists. Both FDA-approved for weight loss. Both producing results that have reshaped how providers think about treating obesity. So which one is right for you?

The answer depends on your biology, not a headline. At Med Matrix, we run a 100-biomarker lab panel before prescribing either medication. That panel tells us whether semaglutide, tirzepatide, or a different approach altogether makes the most sense for your body.

How Semaglutide Works

Semaglutide targets the GLP-1 receptor. GLP-1 (glucagon-like peptide-1) is a hormone your body produces naturally after eating. It signals fullness, slows stomach emptying, and helps regulate blood sugar.

When you take semaglutide, that signal gets amplified. Appetite drops. The constant "food noise" quiets down. Patients describe it as the first time they can eat a normal portion and feel satisfied.

Brand names you may recognize: Ozempic (approved for type 2 diabetes) and Wegovy (approved for weight management). Same molecule, different dosing and indication.

Clinical trials showed patients on semaglutide lost an average of 15% of their body weight over 68 weeks. For someone at 250 pounds, that's roughly 37 pounds.

How Tirzepatide Works

Tirzepatide does what semaglutide does, plus more. It activates two receptors: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). GIP is another incretin hormone involved in insulin secretion and fat metabolism.

By hitting both receptors, tirzepatide may produce greater appetite suppression and improved metabolic signaling in some patients. Brand names: Mounjaro (diabetes) and Zepbound (weight management).

In head-to-head trials, tirzepatide produced slightly more weight loss than semaglutide on average. The SURMOUNT trials showed weight loss of up to 22.5% of body weight at the highest dose over 72 weeks.

Side Effects: What to Expect

Both medications share similar side effects, primarily gastrointestinal:

• Nausea (most common, usually worst in the first few weeks)
• Constipation or diarrhea
• Stomach discomfort
• Reduced appetite (this is the intended effect, but it can feel intense initially)

Tirzepatide tends to have similar rates of nausea but may cause slightly more GI effects at higher doses due to the dual-receptor mechanism. Both medications are titrated gradually, starting at a low dose and increasing over weeks, specifically to minimize these effects.

At Med Matrix, your provider monitors your labs throughout the process. If nausea lingers or your metabolic markers shift unexpectedly, your protocol gets adjusted. You're not left guessing.

The Part Most Clinics Skip

A prescription by itself is incomplete. Stubborn weight often has drivers that no GLP-1 medication addresses on its own: thyroid dysfunction, insulin resistance, cortisol imbalance, sex hormone shifts, chronic inflammation, nutrient deficiencies.

If your thyroid is underactive and nobody catches it, you'll lose some weight on semaglutide and plateau. If insulin resistance is the primary driver, tirzepatide's GIP activity might give you an edge, but you still need the metabolic picture to confirm.

We test over 100 biomarkers before prescribing. Thyroid panel (TSH, free T3, free T4, reverse T3, antibodies). Fasting insulin and glucose. A1C. Full lipid panel with particle size. Inflammatory markers. Sex hormones. Metabolic markers. InBody 770 body composition scan.

That data tells your provider which medication to prescribe, what dosing schedule to use, and what other factors to address at the same time.

Which One Should You Choose?

There is no universal answer. Both medications work. The right choice depends on:

• Your metabolic profile (insulin resistance, A1C, fasting glucose patterns)
• Your health history and any existing conditions
• How your body responds to GLP-1 signaling
• Cost and availability (tirzepatide is generally more expensive, though compounding pharmacies may offer alternatives)
• Your provider's clinical judgment based on your full lab panel

Some patients do better on semaglutide. Some respond more strongly to tirzepatide. Some start on one and switch. The point is that the decision should come from data, not marketing.

What Happens at Med Matrix

Your first visit is a 30-minute testing appointment. We draw blood for a 100-biomarker panel and run an InBody 770 body composition scan. Your provider reviews everything before your one-hour consultation, where you go over every result together and decide on a plan.

If a GLP-1 medication fits your profile, your provider prescribes it as part of a protocol that includes nutrition guidance, body composition tracking, and ongoing lab monitoring. Follow-up visits track your progress and adjust your plan as your body responds.

Full onboarding runs approximately $1,200 to $1,500. Medication costs vary depending on your protocol. We accept HSA, FSA, CareCredit, and all major cards. New patients receive a $100 voucher toward their first visit.

Get Your Free Guide + $100 Voucher and take the first step toward finding the right approach for your body.